Twist Bioscience Names Solange Glaize As Chief Financial Officer

SAN FRANCISCO, June 16, 2015 /PRNewswire/ -- Twist Bioscience, a company focused on synthetic DNA, today announced the appointment of Solange Glaize, former corporate controller and chief accounting officer for Agilent Technologies, to the newly created position of chief financial officer.

Twist Bioscience Logo
"We are thrilled to welcome Solange to our executive team, as she will be instrumental in helping us build a world-renowned organization and execute on our commercial and operational goals," said Emily Leproust, Ph.D., chief executive officer of Twist Bioscience. "With the successful completion of our recent Series C financing, we are poised to scale our synthetic DNA manufacturing capability, expand our customer base and evaluate strategic opportunities, driving toward a full commercial launch in 2016."

Ms. Glaize brings more than 25 years of finance leadership to Twist Bioscience. Most recently, she served as vice president, corporate controller and chief accounting officer for Agilent Technologies, where she was responsible for the entire accounting function, international country controllership, external financial reporting, the Enterprise Sarbanes Oxley program, and financial policies, processes and solutions. Prior to that Ms. Glaize served as the life sciences group (LSG) operational CFO and also headed the LSG's business development organization. She joined Agilent with the spinoff from Hewlett-Packard and served as managing director of European financial services in Brussels, Belgium. She transferred in 2001 to the Bay Area and subsequently held several finance controller roles, including commercial controller of the semi-conductor products group and manufacturing controller for the life sciences and chemical analysis group.

Ms. Glaize began her career with Hewlett Packard, where she held a variety of escalating finance and managerial roles both in Europe and the United States. She obtained her M.S. in Management from HEC School of Management in Paris, France.

"It is an exciting time to join the talented team at Twist Bioscience," commented Ms. Glaize. "After a long tenure with Fortune 500 companies, I look forward to applying my financial expertise to contribute to the next phase of growth and continued execution of our business strategy."


At Twist Bioscience, our expertise is synthetic DNA. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. The Twist Bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. For more information, please visit Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at

Logo -


To view the original version on PR Newswire, visit:

SOURCE Twist Bioscience